Glial and Neural Stem Cells as New Therapeutic Targets for Neurodegenerative Disorders

2020 ◽  
Author(s):  
Sara Xapelli ◽  
Maria J. Diógenes ◽  
Vincenzo Crunelli ◽  
Carlos P. Fitzsimons ◽  
Sandra H. Vaz

2015 ◽  
Vol 5 (6) ◽  
pp. 1023-1038 ◽  
Author(s):  
Karen L. Ring ◽  
Mahru C. An ◽  
Ningzhe Zhang ◽  
Robert N. O’Brien ◽  
Eliana Marisa Ramos ◽  
...  

2019 ◽  
Vol 28 (9-10) ◽  
pp. 1140-1154
Author(s):  
Aleksandra Klimczak ◽  
Urszula Kozłowska ◽  
Joanna Sanford ◽  
Piotr Walczak ◽  
Izabela Małysz-Cymborska ◽  
...  

Neurodegeneration can be defined as a process in which neuronal structures and functions undergo changes leading to reduced neuronal survival and increased cell death in the central nervous system (CNS). Neuronal degeneration in specific regions of the CNS is a hallmark of many neurodegenerative disorders, and there is reliable proof that neural stem cells bring therapeutic benefits in treatment of neurological lesions. However, effective therapy with neural stem cells is associated with their biological properties. The assessment of immunological properties and comprehensive studies on the biology of glial restricted progenitors (GRP) are necessary prior to the application of these cells in humans. This study provides an in vitro characterization of the QSV40 glial human cell line, as well as murine and canine primary culture suspensions of GRPs and their mature, astrocytic forms using flow cytometry and immunohistochemical staining. Cytokines and chemokines released by GRPs were assessed by Multiplex ELISA. Some immunological differences observed among species suggest the necessity of reconsidering the pre-clinical model, and that careful testing of immunomodulatory strategies is required before cell transplantation into the CNS can be undertaken.


2005 ◽  
Vol 26 (4) ◽  
pp. 703-711 ◽  
Author(s):  
Fariba Behbod ◽  
Jeffrey M. Rosen

Cell Cycle ◽  
2013 ◽  
Vol 13 (2) ◽  
pp. 268-278 ◽  
Author(s):  
Maria Grazia Cipolleschi ◽  
Ilaria Marzi ◽  
Roberta Santini ◽  
David Fredducci ◽  
Maria Cristina Vinci ◽  
...  

Oncotarget ◽  
2014 ◽  
Vol 5 (22) ◽  
pp. 11029-11037 ◽  
Author(s):  
Rebecca Lamb ◽  
Hannah Harrison ◽  
James Hulit ◽  
Duncan L. Smith ◽  
Michael P. Lisanti ◽  
...  

Molecules ◽  
2019 ◽  
Vol 24 (7) ◽  
pp. 1350 ◽  
Author(s):  
Rui Rodrigues ◽  
Diogo Lourenço ◽  
Sara Paulo ◽  
Joana Mateus ◽  
Miguel Ferreira ◽  
...  

With the increase of life expectancy, neurodegenerative disorders are becoming not only a health but also a social burden worldwide. However, due to the multitude of pathophysiological disease states, current treatments fail to meet the desired outcomes. Therefore, there is a need for new therapeutic strategies focusing on more integrated, personalized and effective approaches. The prospect of using neural stem cells (NSC) as regenerative therapies is very promising, however several issues still need to be addressed. In particular, the potential actions of pharmacological agents used to modulate NSC activity are highly relevant. With the ongoing discussion of cannabinoid usage for medical purposes and reports drawing attention to the effects of cannabinoids on NSC regulation, there is an enormous, and yet, uncovered potential for cannabinoids as treatment options for several neurological disorders, specifically when combined with stem cell therapy. In this manuscript, we review in detail how cannabinoids act as potent regulators of NSC biology and their potential to modulate several neurogenic features in the context of pathophysiology.


Sign in / Sign up

Export Citation Format

Share Document